Vaccines & Antivirals — Vaccines and antiviral principles (overview)

For most of human history, viral diseases such as smallpox, polio, and influenza caused devastating epidemics with no effective countermeasures. The concept of deliberately inducing immunity long predates the germ theory of disease; Chinese physicians practiced variolation — inoculating healthy individuals with material from mild smallpox lesions — as early as the tenth century. Yet it was Edward Jenner's systematic demonstration in 1796 that inoculation with cowpox (vaccinia) could protect against smallpox that established the scientific foundation for vaccination. This landmark experiment showed that a related, less virulent pathogen could elicit cross-protective immunity, a principle that remains central to modern vaccinology.

These milestones reveal a persistent challenge: viruses hijack host cell machinery for replication, making them difficult to target without harming the host. Two complementary strategies have emerged to address this problem. Vaccines train the adaptive immune system to recognize and neutralize a pathogen before or during early infection, while antiviral drugs directly interfere with specific steps in the viral replication cycle. Understanding both approaches requires knowledge of viral biology, host immunity, and pharmacological design — the themes explored throughout this lesson.

At the heart of both vaccination and antiviral therapy lies the viral replication cycle — a sequence of molecular events that begins with attachment to a host cell and culminates in the release of new virions. Every step in this cycle represents a potential target for therapeutic intervention or a source of antigens that the immune system can learn to recognize. The following foundational concepts govern vaccine design and antiviral pharmacology.

The diagram below illustrates the major vaccine platform types and the immunological cascade they initiate. Each platform delivers or encodes viral antigens through a different mechanism, but all converge on the same endpoint: presentation of antigenic peptides on MHC class I and class II molecules, activating both cytotoxic T lymphocytes (CTLs) and helper T cells that drive B-cell maturation and antibody production.

Notice that live-attenuated and viral-vector platforms produce antigens endogenously within host cells, meaning peptides are loaded onto both MHC I and MHC II molecules, eliciting robust CTL responses in addition to antibody production. Inactivated and subunit vaccines, by contrast, primarily enter the exogenous pathway (MHC II), generating strong humoral immunity but relatively weaker cellular responses — a distinction with important clinical implications for intracellular pathogens. The mRNA platform, encapsulated in lipid nanoparticles, is translated by host ribosomes in the cytoplasm, effectively mimicking endogenous antigen production while avoiding the safety concerns of replicating viruses.

Antiviral drug design is fundamentally constrained by the fact that viruses are obligate intracellular parasites — they co-opt host ribosomes, membranes, and metabolic intermediates. A successful antiviral must therefore target steps that rely on virus-specific enzymes or structures absent from uninfected cells. The viral replication cycle can be divided into discrete stages, each presenting unique pharmacological opportunities.

Key Antiviral Targets by Replication Stage

A unifying pharmacological concept is that of nucleoside/nucleotide analogues, which form the largest class of antivirals. These compounds mimic natural substrates of viral polymerases but, once incorporated into the growing nucleic acid chain, either terminate elongation (obligate chain terminators like acyclovir triphosphate) or introduce errors that push the viral population past an error catastrophe threshold (mutagenic agents like favipiravir). The selectivity of acyclovir, for instance, arises because it requires initial phosphorylation by the herpes simplex virus thymidine kinase — an enzyme absent in uninfected cells — thereby concentrating the active triphosphate form exclusively in infected cells.

Modern vaccinology encompasses a spectrum of platforms, each with distinct advantages regarding manufacturing scalability, cold-chain requirements, immunogenicity profile, and safety considerations. The diagram below organizes these platforms along a continuum from whole-organism approaches to molecularly defined constructs, illustrating how the trade-off between immunogenicity and safety shifts across the spectrum.

Vaccine Platform Comparison

Consider a clinical trial of a novel influenza vaccine. In the placebo group (n = 10,000), 500 individuals contract influenza during the study period. In the vaccinated group (n = 10,000), 50 individuals contract influenza. Influenza has an estimated R₀ of 2.0. We will calculate vaccine efficacy, the herd immunity threshold, and the minimum vaccination coverage needed to achieve Rₑ < 1.

Vaccines and antivirals represent fundamentally different but complementary approaches to controlling viral disease. Vaccines are prophylactic interventions that prevent infection or reduce disease severity in advance, while antivirals are primarily therapeutic, administered after infection to limit viral replication and reduce morbidity. The table below highlights critical differences in mechanism, timing, scope, and public health impact.

The principles covered in this overview serve as the foundation for several rapidly evolving areas of research. Understanding classical vaccine immunology and antiviral pharmacology prepares students to engage with cutting-edge developments that are reshaping virology and immunology.

Another transformative development is the use of CRISPR-based antivirals, in which programmable Cas13 nucleases are directed to cleave viral RNA genomes inside infected cells. While still largely at the preclinical stage, this approach exemplifies the convergence of molecular biology, immunology, and gene editing that students will encounter in advanced virology and biotechnology courses. Similarly, broadly neutralizing antibodies (bNAbs) isolated from elite controllers of HIV are being developed as both therapeutic agents and templates for rational vaccine design — a powerful illustration of how understanding natural immunity informs both prophylactic and therapeutic strategies.